Skip to main content
SpringerLink
Log in

Alpha-2 Adrenergic Agonists in Children with Inattention, Hyperactivity and Impulsiveness

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Although originally developed for the treatment of hypertension, α2-agonists have been used to treat Tourette’s syndrome, attention-deficit hyperactivity disorder (ADHD), developmental disorders and substance abuse for nearly three decades. Based on studies of clonidine, α2-agonists were presumed to reduce arousal by decreasing the firing of noradrenaline neurons in locus ceruleus. Accumulated preclinical evidence indicates that guanfacine has features in common with clonidine, in addition to other pharmacological effects. Clonidine binds to the three subtypes of α2-receptors, A, B and C, whereas guanfacine binds more selectively to α2A-receptors, which appears to enhance prefrontal function. Several reports on the use of the α2-agonists show improvements in children with ADHD and improvements in hyperactivity, impulsiveness and inattention in children with tic disorders and pervasive developmental disorders. Both clonidine and guanfacine are associated with sedation, fatigue and somnolence. Reductions in heart rate and blood pressure are modest and rarely lead to discontinuation of treatment across these trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I

Similar content being viewed by others

References

  1. Cohen DJ, Young JG, Nathanson JA, et al. Clonidine in Tourette’s syndrome. Lancet 1979; 2(8142): 551–3

    Article  CAS  Google Scholar 

  2. Gold MS, Redmond Jr DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2(8090): 599–602

    Article  CAS  Google Scholar 

  3. Riddle MA, Bernstein GA, Cook EH, et al. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 1999; 38(5): 546–56

    Article  CAS  Google Scholar 

  4. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53(5): 448–55

    CAS  PubMed  Google Scholar 

  5. Arnsten AFT. Alpha-2 agonists in the treatment of ADHD. Medscape Psychiatry & Mental Health 2007 [online]. Available from URL: http://www.medscape.com/viewarticle/560074 [Accessed 2008 Aug 24]

  6. Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007; 129(2): 397–410

    Article  CAS  Google Scholar 

  7. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988; 8(11): 4287–98

    Article  CAS  Google Scholar 

  8. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985; 24(5): 617–29

    Article  CAS  Google Scholar 

  9. MacDonald E, Kobilka BK, Scheinin M. Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997; 18(6): 211–9

    Article  CAS  Google Scholar 

  10. Rubia K, Smith AB, Brammer MJ, et al. Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. Neuroimage 2003; 20(1): 351–8

    Article  Google Scholar 

  11. Jakala P, Riekkinen M, Sirvio J, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 1999; 20(5): 460–70

    Article  CAS  Google Scholar 

  12. Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23Suppl. 1: 33–41

    Article  CAS  Google Scholar 

  13. Balldin J, Berggren U, Eriksson E, et al. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion— a comparison with clonidine. Psychoneuroendocrinology 1993; 18(1): 45–55

    Article  CAS  Google Scholar 

  14. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens 2007;9(5): 399–405

    Article  CAS  Google Scholar 

  15. Sarlis NJ, Caticha O, Anderson JL, et al. Hyperadrenergic state following acute withdrawal from clonidine used at supra therapeutic doses. Clin Auton Res 1996; 6(2): 115–7

    Article  CAS  Google Scholar 

  16. Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman’s the pharmaceutical basis of therapeutics. New York (NY): McGraw-Hill, 2008: 237–96

    Google Scholar 

  17. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38(12): 1551–9

    Article  CAS  Google Scholar 

  18. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158(7): 1067–74

    Article  CAS  Google Scholar 

  19. Tourette syndrome (TS) Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58(4): 527–36

    Article  Google Scholar 

  20. Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002; 25(6): 325–32

    Article  CAS  Google Scholar 

  21. Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47(2): 180–8

    Article  Google Scholar 

  22. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008; 29(4): 303–8

    Article  Google Scholar 

  23. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121(1): e73–84

    Article  Google Scholar 

  24. Sallee FR, McGough J, Wigal T, et al., for the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 155–65

    Article  Google Scholar 

  25. Scahill L, Erenberg G, Berlin CM, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006; 3(2): 192–206

    Article  CAS  Google Scholar 

  26. Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA) Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multi-modal Treatment Study of children with Attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088–96

    Article  Google Scholar 

  27. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47(2): 189–98

    PubMed  Google Scholar 

  28. Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50–4

    Article  CAS  Google Scholar 

  29. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34: 1140–6

    Article  CAS  Google Scholar 

  30. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995; 5: 215–23

    Article  Google Scholar 

  31. DuPaul GJ, Ervin RA, Hook CL, et al. Peer tutoring for children with attention deficit hyperactivity disorder: effects on classroom behavior and academic performance. J Appl Behav Anal 1998; 31: 579–92

    Article  CAS  Google Scholar 

  32. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89(5): 485–91

    CAS  PubMed  Google Scholar 

  33. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16(5): 589–98

    Article  Google Scholar 

  34. Boreman CD, Arnold LE. Hallucinations associated with initiation of guanfacine. J Am Acad Child Adolesc Psychiatry 2003; 42(12): 1387

    Article  Google Scholar 

  35. Luthra V, Markov D, Ambrosini P. Does guanfacine cause hallucinations in children? J Child Adolesc Psychopharmacol 1999; 9(4): 313–4

    Article  CAS  Google Scholar 

  36. Horrigan JP, Barnhill LJ. Guanfacine and secondary mania in children. J Affect Disord 1999; 54(3): 309–14

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Lawrence Scahill, MSN, PhD, has been a consultant for Bristol-Myers Squibb, Janssen Pharmaceuticals Inc., Neuropharm, Shire Pharmaceuticals Inc. and Supernus Pharmaceuticals Inc.

Author information

Authors and Affiliations

  1. Child Study Center, Yale University School of Medicine and Yale School of Nursing, 230 South Frontage Rd, New Haven, Connecticut, 06520, USA

    Lawrence Scahill

Authors
  1. Lawrence Scahill
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scahill, L. Alpha-2 Adrenergic Agonists in Children with Inattention, Hyperactivity and Impulsiveness. CNS Drugs 23 (Suppl 1), 43–49 (2009). https://doi.org/10.2165/00023210-200923000-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200923000-00006

Keywords

Search

Navigation